ERβ deletion has recently been reported to collaborate with p53 inactivation to induce early onset breast tumors in mice [37] suggesting that ERβ synergizes with wild-type p53 to elicit anti-tumor activities in breast cancer cells. Here, TP53 is linked to breast cancer.